Wall Street Zen Upgrades Sutro Biopharma Stock Rating

Analysts raise STRO from 'sell' to 'hold' rating amid mixed reviews

Mar. 28, 2026 at 5:33am

Got story updates? Submit your updates here. ›

Wall Street Zen, a research firm, has upgraded its rating on Sutro Biopharma (NASDAQ:STRO) from 'sell' to 'hold'. This comes as the biopharmaceutical company's stock has seen a mix of ratings from various analysts, with some raising their price targets and others maintaining a more cautious outlook.

Why it matters

Sutro Biopharma is a clinical-stage biotech focused on developing novel biologic drug candidates in oncology and immunology. The company's stock performance and analyst ratings can impact investor sentiment and the perceived value of its pipeline, which is important for a pre-revenue biotech like Sutro.

The details

Wall Street Zen upgraded Sutro Biopharma from a 'sell' rating to a 'hold' rating in a research report issued on Saturday. Several other research firms have also weighed in on Sutro recently, with some raising their price targets and ratings, while others have maintained more cautious stances. For example, Citizens Jmp upgraded Sutro from 'market perform' to 'market outperform' and set a $23 price target, while Weiss Ratings reiterated a 'sell (d-)' rating.

  • Wall Street Zen issued its upgraded rating on Sutro Biopharma on Saturday, March 28, 2026.

The players

Wall Street Zen

A research firm that covers Sutro Biopharma and recently upgraded the stock from a 'sell' to a 'hold' rating.

Citizens Jmp

A research firm that upgraded Sutro Biopharma from a 'market perform' rating to a 'market outperform' rating and set a $23 price target.

Weiss Ratings

A research firm that reiterated a 'sell (d-)' rating on Sutro Biopharma's stock.

Got photos? Submit your photos here. ›

The takeaway

Sutro Biopharma's stock has seen a mix of analyst ratings, with some firms upgrading the company while others maintain a more cautious outlook. This reflects the complex and uncertain nature of the biotech industry, where pipeline progress and regulatory approvals can significantly impact a company's valuation and future prospects.